NASDAQ$INTS
Intensity Therapeutics Inc · Q3 2024 earnings
Q3 2024 earnings · · Investor relations
Briefing
Announced third quarter 2024 financial results and provided a corporate update.
Intensity Therapeutics reported a net loss of $3.5 million for the third quarter of 2024. The company's cash and cash equivalents totaled $2.8 million as of September 30, 2024, expected to fund operations into the first quarter of 2025. The first patient was dosed in randomized, Phase 2 study in presurgical triple negative breast cancer
- First patient dosed in randomized, Phase 2 study in presurgical triple negative breast cancer
- INVINCIBLE-3 Study: first patients were dosed in the U.S.
- INVINCIBLE-3 Study: authorization received from Health Canada to initiate the study in Canada, The European Medicines Agency to initiate the study in Europe, and Australia's Therapeutic Goods Administration to initiate study in Australia.
- INVINCIBLE-4 Study: first patient dosed in the INVINCIBLE-4 Study.
Headline financials
Revenue & EPS history
Intensity Therapeutics · Revenue · Quarterly
$0
Forward guidance
The Company expects that cash and cash equivalents will be sufficient to fund operations into the first quarter in 2025.
Historical earnings impact
How earnings announcements have historically affected this stock's price.
Avg. return before/after earnings
Based on 15 quarterly earnings reports · overlaid with Q3 2024
+0.8%
Avg return
Earnings day
-4.7%
Avg return
5 days after
+26.6%
Avg return
30 days after
40%
6 / 15 earnings
Positive
+17.3%
Q4 2023
Best reaction
-6.2%
Q3 2024
Worst reaction
| Quarter | Report date | Reaction (Day 0) | +5 days | +30 days |
|---|---|---|---|---|
| Q4 2026 | +4.4% | -6.7% | -26.9% | |
| Q3 2025 | -5.8% | -16.0% | -8.2% | |
| Q2 2025 | +7.2% | +15.1% | +11.9% | |
| Q1 2025 | -5.8% | -22.6% | -38.6% | |
| Q4 2024 | +0.5% | -18.3% | -18.7% | |
| Q3 2024 | -6.2% | -7.4% | -39.2% | |
| Q2 2024 | -4.2% | -11.1% | -17.1% | |
| Q1 2024 | +6.7% | +17.9% | +27.5% | |
| Q1 2023 | +6.7% | +17.9% | +27.5% | |
| Q4 2023 | +17.3% | +22.0% | +12.0% | |
| Q3 2023 | -4.0% | -22.8% | +263.2% | |
| Q3 2022 | -4.0% | -22.8% | +263.2% | |
| Q4 2022 | -0.4% | -5.1% | -19.0% | |
| Q2 2023 | -0.4% | -5.1% | -19.0% | |
| Q2 2022 | -0.4% | -5.1% | -19.0% | |
| Q1 2022 | — | — | — | |
| Q4 2021 | — | — | — | |
| Q3 2021 | — | — | — | |
| Q2 2021 | — | — | — | |
| Q1 2021 | — | — | — | |
| Q4 2020 | — | — | — |
Discussion
Share your read of this quarter. Sign-in carries your eToro identity.
Join the conversation
Sign in with eToro to post your read of this quarter and vote on others'.
Sign in with eToro